Indivior Pharmaceuticals Inc(INDV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:40 PM ET (Korea 10/31 08:40)
Full metrics table
| Index | RUT | P/E | 9.79 | EPS (ttm) | 3.61 | Insider Own | 3% | Shs Outstand | 124.8M | Perf Week | 2.61% |
| Market Cap | 4.17B | Forward P/E | 8.15 | EPS next Y | 7.27% | Insider Trans | -1.94% | Shs Float | 121.0M | Perf Month | -0.03% |
| Enterprise Value | 4.37B | PEG | 0.33 | EPS next Q | 0.99 | Inst Own | 97.24% | Short Float | 7.78% | Perf Quarter | -5.35% |
| Income | 0.45B | P/S | 3.04 | EPS this Y | 61.75% | Inst Trans | -8.76% | Short Ratio | 3.94 | Perf Half Y | -6.08% |
| Sales | 1.37B | P/B | - | EPS next 5Y | 24.63% | ROA | 32.75% | Short Interest | 9.41M | Perf YTD | -1.42% |
| Book/sh | -0.51 | P/C | 13.69 | EPS past 3/5Y | - | ROE | - | 52W High | -17.38% ($42.81) | Perf Year | 21.42% |
| Cash/sh | 2.58 | P/FCF | 160.82 | Sales past 3/5Y | 11.2% 13.88% | ROIC | - | 52W Low | 27.78% ($27.68) | Perf 3Y | 80.46% |
| Dividend Est. | - | EV/EBITDA | 6.9 | EPS Y/Y TTM | 265.06% | Gross Margin | 85.08% | Volatility(W/M) | 4.03% 3.54% | Perf 5Y | 108.68% |
| Dividend TTM | - | EV/Sales | 3.18 | Sales Y/Y TTM | 16.44% | Oper. Margin | 45.05% | ATR (14) | 1.23 | Perf 10Y | 82.32% |
| Dividend Ex-Date | 2026/11/3 | Quick Ratio | 0.5 | EPS Q/Q | 244.87% | Profit Margin | 32.75% | RSI (14) | 52.24 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.62 | Sales Q/Q | 13.38% | SMA20 | 1.21% ($34.95) | Beta | 1.14 | Target Price | $49.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/29 | SMA50 | 0.49% ($35.2) | Rel Volume | 1.93 | Prev Close | $35.25 |
| Employees | 838 | LT Debt/Eq | - | EPS/Sales Surpr. | 24.45% 8.09% | SMA200 | -0.83% ($35.67) | Avg Volume(3M) | 2.39M | Price | $35.37 |
| IPO | 2014/12/29 | Option/Short | Yes/Yes | Trades | 22603 | Volume | 4,605,647 | Change | 0.34% |
💊 A specialty pharmaceutical company that develops and sells treatments for opioid use disorder. It leads the opioid use disorder treatment market through products such as the once-monthly injectable therapy SUBLOCADE and a sublingual film treatment, and has secured a differentiated position in the long-acting injectable segment. It is a specialty pharmaceutical company focused on addiction treatment.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
Traded more than usual. That is 193% of its average volume.
Ex-dividend date: November 3
1 days to go. Buy before this date to receive the dividend.
INDV makes money but has a weak balance sheet
Of every $100 in sales, $45.05 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +61.8% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $690. Peers typically go for $1,453. Compared with its own 2-year average, it is 53% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +108.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 97.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #15 of 83 in the industry
Based on market cap of $4B.
INDV#15 Indivior Pharmaceuticals Inc $4B PER 9.8 
LQDA#16 Liquidia Corp $4B PER 33.0 
AMLX#17 Amylyx Pharmaceuticals Inc $4B PER - 
RGC#18 Regencell Bioscience Holdings Ltd $3B PER - 
BHC#19 Bausch Health Companies Inc $3B PER - 
FAQ
What kind of company is INDV?
INDV belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of INDV?
The market cap of INDV is approximately $4.2B, ranking 1,504 within its sector.
What is the P/E ratio of INDV?
INDV has a P/E ratio of approximately 9.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INDV?
INDV has recorded a 52-week high of $42.81 and a low of $27.68.
